Rotigotine (1 brand name, 1 dosage form, 1 route)
Available dosage forms: FILM, EXTENDED RELEASE.
Routes of administration: TRANSDERMAL.
Brand Names
- NEUPRO
Contraindications
NEUPRO is contraindicated in patients who have demonstrated hypersensitivity to rotigotine or the components of the transdermal system.
Adverse Reactions
The following serious adverse reactions are discussed below and elsewhere in the labeling: Sulfite Sensitivity [see Warnings and Precautions (5.1)] Falling Asleep During Activities of Daily Living and Somnolence [see Warnings and Precautions (5.2)] Hallucinations/Psychosis [see Warnings and Precautions (5.3)] Symptomatic Hypotension [see Warnings and Precautions (5.4)] Syncope [see Warnings and Precautions (5.5)] Impulse Control/Compulsive Behaviors [see Warnings and Precautions (5.6)] Elevation of Blood Pressure and Heart Rate [see Warnings and Precautions (5.7)] Weight Gain and Fluid Retention [see Warnings and Precautions (5.8)] Dyskinesia [see Warnings and Precautions (5.9)] Application Site Reactions [see Warnings and Precautions (5.10)] Augmentation and Rebound in RLS [see Warnings and Precautions (5.11)] Hyperpyrexia and Confusion [see Warnings and Precautions (5.14)] Withdrawal Symptoms [see Warnings and Precautions (5.15)] Fibrotic Complications [see Warnings and Precautions (5.16)]
Mechanism of Action
Rotigotine is a non-ergoline dopamine agonist. The precise mechanism of action of rotigotine as a treatment for Parkinson’s disease is unknown, although it is thought to be related to its ability to stimulate dopamine receptors within the caudate-putamen in the brain. The precise mechanism of action of rotigotine as a treatment for Restless Legs Syndrome is unknown but is thought to be related to its ability to stimulate dopamine receptors.